Medication Sector in Qatar: Hand in Hand Facing the Blockade

PHARMACEUTICAL INDUSTRY IN QATAR
DR. AHMED AL-MOHANNADI
CEO, Q LIFE PHARMA
Disclosure of Conflict of Interest

Presenting Authors Have No Relationships to Disclose
“Medication Sector in Qatar”
After Math
Hand in Hand Facing the Embargo

Dr. Ahmed Al Mohannadi
10th Mar 2018
MANY THANKS TO HIS HIGHNESS EMIR OF QATAR
OVERVIEW:

- Current Pharma Market Share of Qatar
- Consequences of depending on other countries
- Main challenges and barriers of local production of medicines in Qatar
- How to overcome the challenges and barriers
- Advantages of producing locally
- Conclusion
Estimated Current Market Share

- GCC - 1% of world pharma business (13 billion USD)
- Qatar shows approximately 600 million USD
Brands and Generics
537.453 MN USD

- BRANDS - 430 mn USD
- GENERICS - 107 mn USD
Existing Pharmaceutical Companies

- Q Life Pharma
- Qatar Pharma
- Qatar German
Medicine Availability Before and After Blockade

**BEFORE**

- Imported Brands & Generic medicines from the GCC & around the world

**AFTER**

- Stopped importing Generics from KSA, UAE, Bahrain and Egypt
- Started Importing Generics and Brands from around the world at a higher price
Consequences of depending on importing from other countries

1. Sudden discontinuation from supplying countries
2. Big shortage of trusted medicines
3. High cost of purchases
4. No self-sufficiency in Medicines
5. No well-established R&D in the country
Advantages of producing locally

1. No effect by discontinuation of supplying countries.
2. No shortage of essential medicines.
3. High cost of purchase can be controlled.
4. Self-sufficiency in Medicines.
5. Country owned R&D.
6. New job creation.
7. Export Business.
Main Challenges and Barriers of Local Manufacturer

- Technology and knowledge transfer
- Small market for Generic medicines
- Very high overheads
- Scarcity of Qatari Human resources in the Pharmaceutical industry
- Lack of raw materials
- Complicated rules and regulations
- Delayed documentation
- Qatar is not one of the reference countries in medicine
Establishing new rules and regulations to counter the new situation

Prioritizing Qatari products

Registration control on similar generic products that are already produced in Qatar

Enforcing a law to encourage international innovator manufactures to corporate with local manufacturers (Under license)

Fast track approval for all pharmaceutical files

Encourage pharmaceutical engineering course by universities in Qatar
CONCLUSION:

PROMOTE THE PRODUCTION OF PHARMACEUTICALS & GENERICS WITH THE HELP OF LOCALLY REGISTERED COMPANIES
Thank You